Valuation: Polaris Group

Market Cap 8.86B 277M 239M 225M 205M 385M 26.57B 391M 2.64B 1.04B 13.29B 1.04B 1.02B 44.26B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.37B 293M 253M 238M 217M 408M 28.12B 414M 2.8B 1.1B 14.06B 1.1B 1.08B 46.84B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-4.63%
1 week-6.36%
Current month-5.07%
1 month-15.57%
3 months-36.22%
6 months-65.55%
Current year-66.88%
1 week 10.15
Extreme 10.15
11.25
1 month 10.15
Extreme 10.15
12.65
Current year 10.15
Extreme 10.15
35.95
1 year 10.15
Extreme 10.15
44.55
3 years 10.15
Extreme 10.15
88.1
5 years 10.15
Extreme 10.15
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 28/02/2019
Chief Operating Officer - 31/01/2019
Chief Executive Officer - 30/04/2014
Director TitleAgeSince
Chairman 64 23/11/2014
Director/Board Member - 24/02/2020
Director/Board Member - 02/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-4.63%-6.36%-70.66%-87.91% 277M
+0.18%-0.07%+1.00%+20.41% 48.63B
+1.89%+5.08%+492.59%+629.24% 46.3B
+1.83%+2.75%+15.61%+91.22% 41.97B
-0.50%-1.56%+24.67%+12.17% 39.51B
-2.74%-7.13%+18.72%+49.04% 31.75B
-1.14%-2.51%+27.52%+136.42% 16.48B
+0.59%-2.25% - - 16.34B
-0.14%-0.06%+2.60%+29.39% 14B
-2.60%-1.00%+77.85%+40.37% 13.33B
Average -0.72%-1.39%+65.54%+102.26% 26.86B
Weighted average by Cap. +0.07%-0.36%+105.40%+155.27%

Financials

2024 2025
Net sales 107M 3.35M 2.89M 2.72M 2.47M 4.65M 321M 4.72M 31.93M 12.51M 161M 12.58M 12.3M 535M 40.6M 1.27M 1.1M 1.03M 939K 1.77M 122M 1.79M 12.12M 4.75M 60.91M 4.77M 4.67M 203M
Net income -2.5B -78.35M -67.67M -63.67M -57.87M -109M -7.51B -110M -747M -293M -3.75B -294M -288M -12.51B -3.93B -123M -106M -99.91M -90.81M -171M -11.78B -173M -1.17B -459M -5.89B -462M -452M -19.62B
Net Debt 9.19M 288K 249K 234K 213K 400K 27.57M 406K 2.74M 1.08M 13.79M 1.08M 1.06M 45.93M 517M 16.18M 13.98M 13.15M 11.95M 22.48M 1.55B 22.81M 154M 60.45M 775M 60.76M 59.44M 2.58B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
18/08/26 NT$10.30 -4.63% 2,499,641
17/08/26 NT$10.80 -1.37% 815,383
14/08/26 NT$10.95 -1.35% 435,515
13/08/26 NT$11.10 +1.37% 932,924
12/08/26 NT$10.95 -0.45% 634,528
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock